Cellcyte Genetics (SHPN) 10-K 15 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 14, 2014	Jun. 28, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'Cellcyte Genetics Corp.	'	'
Entity Central Index Key	'0001325279	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$1,070,283
Entity Common Stock, Shares Outstanding	'	82,329,481	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Prepaid expenses and deposits	$9,033	$9,403
Total Current Assets	9,033	9,403
OTHER ASSETS	'	'
Furniture and equipment, net of depreciation and impairment	'	'
Intellectual property, net of amortization and impairment	'	16,218
Total Other Assets	'	16,218
TOTAL ASSETS	9,033	25,621
CURRENT LIABILITIES	'	'
Accounts payable	125,540	73,009
Accrued expenses	82,405	118,850
Due to related parties	140,704	140,704
Note payable - current portion	2,695	2,405
Total Current Liabilities	351,344	334,968
LONG TERM LIABILITIES	'	'
Convertible notes - related party	477,489	346,415
Total Long Term Liabilities	477,489	346,415
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	-819,800	-655,762
Common stock, $0.001 par value; 525,000,000 shares authorized, 82,329,481 shares issued and outstanding, respectively	$82,329	$82,329
Additional paid in capital	11,734,022	11,734,022
Common stock purchase warrants	49,154	49,154
Deficit accumulated during development the stage	-12,685,305	-12,521,267
Total Stockholders' Deficit	-819,800	-655,762
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$9,033	$25,621

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common Stock, $0.001 par value, authorized	525,000,000	525,000,000
Common Stock, $0.001 par value, shares issued and outstanding	82,329,481	82,329,481

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		108 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement [Abstract]	'	'	'
REVENUES	'	'	'
OPERATING EXPENSES:	'	'	'
Consulting	'	'	1,678,107
General and administrative	62,453	74,778	2,663,863
Professional fees	61,696	57,882	1,943,036
Research, development and laboratory	'	'	1,296,619
Salaries and benefits	'	'	1,457,524
Stock-based compensation	'	'	3,025,776
Total Operating Expenses	124,149	132,660	12,064,925
LOSS FROM OPERATIONS	-124,149	-132,660	-12,064,925
OTHER INCOME (EXPENSE)	'	'	'
Interest income	'	'	32,512
Interest and finance charges	-39,889	-33,037	-370,127
Impairment of intellectual property	'	'	-568,913
Impairment of tenant improvements	'	'	-383,535
Gain on extinguishment of debt	'	749,539	803,086
Gain (loss) on disposal of furniture and equipment	'	1,985	-133,403
Total Other Income (Expense)	-39,889	718,487	-620,380
INCOME (LOSS) BEFORE TAXES	-164,038	585,827	-12,685,305
INCOME TAXES	'	'	'
NET INCOME (LOSS)	($164,038)	$585,827	($12,685,305)
NET INCOME (LOSS) PER COMMON SHARE:	'	'	'
Basic	$0	$0.01	'
Diluted	$0	$0.01	'
WEIGHTED AVERAGE COMMON SHARES:	'	'	'
Basic	82,329,481	82,329,481	'
Diluted	82,329,481	88,791,019	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		108 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($164,038)	$585,827	($12,685,304)
Amortization of intellectual property	16,218	7,504	139,111
Depreciation of furniture and equipment	'	7,009	547,247
Stock-based compensation	'	'	3,025,776
Non-cash services	'	'	1,005,082
Amortization of discount on note	600	600	1,800
Warrant issued for legal services	'	'	46,154
Accounts payable paid with common stock	'	'	144,103
Non-cash beneficial conversion right	'	'	36,400
Non-cash impairment of tennant improvements	'	'	383,535
Non-cash impairment of intellectual property	'	'	568,913
Expenses paid by stockholder	'	'	32,755
Accrued interest converted to note payable	63,232	'	63,232
Accrued expense converted to note payable	7,279	'	7,279
Accrued interest reduced in settlement	'	1,385	'
Accounts payable written off	'	-569,812	'
Accounts payable reduced in lease settlement	'	'	520,788
Gain on extinguishment of debt	'	-180,955	-53,547
Loss on disposal of furniture and equipment	'	-1,985	135,388
Other receivables	'	'	'
Prepaid expenses and deposits	370	-728	-8,305
Increase (decrease) in liabilities	'	'	'
Accounts payable	52,531	45,574	560,349
Accrued interest	'	'	82,088
Accrued expenses	-38,850	27,209	52,791
Net cash used by operating activities	-62,658	-78,372	-5,394,365
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Intellectual property acquisition	'	'	-715,528
Cash from sales of equipment	'	1,985	107,465
Furniture and equipment acquisition, net	'	'	-1,327,070
Cash acquired on reverse acquisition	'	'	1,429
Net cash provided by investing activities	'	1,985	-1,933,704
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of convertible notes	61,850	151,387	1,208,882
Proceeds from convertible note allocated to warrant	'	'	3,000
Proceeds from note to fund insurance premiums	32,160	'	32,160
Advances from related party	'	'	112,625
Payments on note payable	-31,352	-75,000	-98,658
Proceeds from sale of common stock	'	'	6,655,889
Net cash provided (used) by financing activities	62,658	76,387	7,913,898
Net (decrease) increase in cash and cash equivalents	'	'	'
Cash and cash equivalents, beginning of period	'	'	'
Cash and cash equivalents, end of period	'	'	'
SUPPLEMENTAL CASH FLOW DISCLOSURES:	'	'	'
Income taxes paid	'	'	'
Interest paid	'	31,332	76,693
NON CASH INVESTING AND FINANCING ACTIVITES	'	'	'
Note payable to related party converted to common stock	'	'	$36,400

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders Equity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005
Initial contribution by founders, in shares	'	'	'	'	'	'	'	'	'
Initial contribution by founds	'	'	'	'	'	'	'	'	$200
Issued on settlement of debt, in shares	'	'	'	'	'	'	'	'	'
Issued on settlement of debt	'	'	'	'	36,400	'	1,017,088	'	'
Issued on exercise of warrants, in shares	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants	'	'	'	'	'	301,597	246,000	'	'
Recapitalization adjustment, in shares	'	'	'	'	'	'	'	'	'
Recapitalization adjustment	'	'	'	'	'	'	-280,632	'	'
Issued for private placement, in shares	'	'	'	'	'	'	'	'	'
Issued for private placement	'	'	'	'	'	382,341	5,971,751	'	'
Stock-based compensation	'	'	163,800	438,690	467,000	176,286	1,780,000	'	'
Reclassification on exercise of warrants	'	'	'	'	'	'	'	'	'
Repricing of warrants	'	'	'	'	'	'	'	'	'
Reclassification on expiration of warrants	'	'	'	'	'	'	'	'	'
Beneficial conversion rights of convertible debt	'	'	'	'	20,000	16,400	'	'	'
Issued for services, in shares	'	'	'	'	'	'	'	'	'
Issued for services	'	'	87,836	98,874	446,273	492,601	'	'	'
Warrant issued with convertible debt	'	'	'	'	3,000	'	'	'	'
Expiration of warrants	'	'	'	'	'	'	'	'	'
Net Income Loss	-164,038	585,827	-359,402	-799,231	-1,420,437	-5,306,159	-4,521,196	-385,639	-315,030
Balance, in shares	'	'	'	'	'	'	'	'	'
Balance	-819,800	-655,762	-1,241,589	-1,133,823	-872,156	-424,392	3,512,542	-700,469	-34,830
Common Stock	'	'	'	'	'	'	'	'	'
Initial contribution by founders, in shares	'	'	'	'	'	'	'	'	37,250,000
Initial contribution by founds	'	'	'	'	'	'	'	'	200
Issued on settlement of debt, in shares	'	'	'	'	1,000,000	'	678,060	'	'
Issued on settlement of debt	'	'	'	'	1,000	'	678	'	'
Issued on exercise of warrants, in shares	'	'	'	'	'	401,008	205,000	'	'
Issued on exercise of warrants	'	'	'	'	'	401	205	'	'
Recapitalization adjustment, in shares	'	'	'	'	'	'	17,740,000	'	'
Recapitalization adjustment	'	'	'	'	'	'	54,790	'	'
Issued for private placement, in shares	'	'	'	'	'	1,529,365	3,981,165	'	'
Issued for private placement	'	'	'	'	'	1,529	3,981	'	'
Stock-based compensation	'	'	'	'	'	'	'	'	'
Reclassification on exercise of warrants	'	'	'	'	'	'	'	'	'
Repricing of warrants	'	'	'	'	'	'	'	'	'
Reclassification on expiration of warrants	'	'	'	'	'	'	'	'	'
Beneficial conversion rights of convertible debt	'	'	'	'	'	'	'	'	'
Issued for services, in shares	'	'	7,773,076	3,475,098	7,161,462	1,135,247	'	'	'
Issued for services	'	'	7,773	3,475	7,161	1,136	'	'	'
Warrant issued with convertible debt	'	'	'	'	'	'	'	'	'
Expiration of warrants	'	'	'	'	'	'	'	'	'
Net Income Loss	'	'	'	'	'	'	'	'	'
Balance, in shares	82,329,481	8,232,948	82,329,481	74,556,405	71,081,307	62,919,845	59,854,225	37,250,000	37,250,000
Balance	82,329	82,329	82,329	74,556	71,081	62,920	59,854	200	200
Additional Paid-In Capital	'	'	'	'	'	'	'	'	'
Initial contribution by founders, in shares	'	'	'	'	'	'	'	'	'
Initial contribution by founds	'	'	'	'	'	'	'	'	'
Issued on settlement of debt, in shares	'	'	'	'	'	'	'	'	'
Issued on settlement of debt	'	'	'	'	35,400	'	1,016,410	'	'
Issued on exercise of warrants, in shares	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants	'	'	'	'	'	301,196	245,795	'	'
Recapitalization adjustment, in shares	'	'	'	'	'	'	'	'	'
Recapitalization adjustment	'	'	'	'	'	'	-538,422	'	'
Issued for private placement, in shares	'	'	'	'	'	'	'	'	'
Issued for private placement	'	'	'	'	'	266,110	4,772,770	'	'
Stock-based compensation	'	'	16,380	438,690	467,000	176,286	1,780,000	'	'
Reclassification on exercise of warrants	'	'	'	'	'	147,071	'	'	'
Repricing of warrants	'	'	'	'	'	-367,366	'	'	'
Reclassification on expiration of warrants	'	'	'	'	'	1,618,295	'	'	'
Beneficial conversion rights of convertible debt	'	'	'	'	20,000	16,400	'	'	'
Issued for services, in shares	'	'	'	'	'	'	'	'	'
Issued for services	'	'	80,063	95,399	392,958	491,465	'	'	'
Warrant issued with convertible debt	'	'	'	'	'	'	'	'	'
Expiration of warrants	'	'	'	'	114,702	'	'	'	'
Net Income Loss	'	'	'	'	'	'	'	'	'
Balance, in shares	'	'	'	'	'	'	'	'	'
Balance	11,734,022	11,734,022	11,734,022	11,490,159	10,956,070	9,926,010	7,276,553	'	'
Common Stock Purchase Warrants	'	'	'	'	'	'	'	'	'
Initial contribution by founders, in shares	'	'	'	'	'	'	'	'	'
Initial contribution by founds	'	'	'	'	'	'	'	'	'
Issued on settlement of debt, in shares	'	'	'	'	'	'	'	'	'
Issued on settlement of debt	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants, in shares	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants	'	'	'	'	'	'	'	'	'
Recapitalization adjustment, in shares	'	'	'	'	'	'	'	'	'
Recapitalization adjustment	'	'	'	'	'	'	203,000	'	'
Issued for private placement, in shares	'	'	'	'	'	'	'	'	'
Issued for private placement	'	'	'	'	'	114,702	1,195,000	'	'
Stock-based compensation	'	'	'	'	'	'	'	'	'
Reclassification on exercise of warrants	'	'	'	'	'	-147,071	'	'	'
Repricing of warrants	'	'	'	'	'	367,366	'	'	'
Reclassification on expiration of warrants	'	'	'	'	'	-1,618,295	'	'	'
Beneficial conversion rights of convertible debt	'	'	'	'	'	'	'	'	'
Issued for services, in shares	'	'	'	'	'	'	'	'	'
Issued for services	'	'	'	'	46,154	'	'	'	'
Warrant issued with convertible debt	'	'	'	'	3,000	'	'	'	'
Expiration of warrants	'	'	'	'	-4,702	'	'	'	'
Net Income Loss	'	'	'	'	'	'	'	'	'
Balance, in shares	'	'	'	'	'	'	'	'	'
Balance	49,154	49,154	49,154	49,154	49,154	114,702	1,398,000	'	'
Retained Earnings / Accumulated Deficit	'	'	'	'	'	'	'	'	'
Initial contribution by founders, in shares	'	'	'	'	'	'	'	'	'
Initial contribution by founds	'	'	'	'	'	'	'	'	'
Issued on settlement of debt, in shares	'	'	'	'	'	'	'	'	'
Issued on settlement of debt	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants, in shares	'	'	'	'	'	'	'	'	'
Issued on exercise of warrants	'	'	'	'	'	'	'	'	'
Recapitalization adjustment, in shares	'	'	'	'	'	'	'	'	'
Recapitalization adjustment	'	'	'	'	'	'	'	'	'
Issued for private placement, in shares	'	'	'	'	'	'	'	'	'
Issued for private placement	'	'	'	'	'	'	'	'	'
Stock-based compensation	'	'	'	'	'	'	'	'	'
Reclassification on exercise of warrants	'	'	'	'	'	'	'	'	'
Repricing of warrants	'	'	'	'	'	'	'	'	'
Reclassification on expiration of warrants	'	'	'	'	'	'	'	'	'
Beneficial conversion rights of convertible debt	'	'	'	'	'	'	'	'	'
Issued for services, in shares	'	'	'	'	'	'	'	'	'
Issued for services	'	'	'	'	'	'	'	'	'
Warrant issued with convertible debt	'	'	'	'	'	'	'	'	'
Expiration of warrants	'	'	'	'	'	'	'	'	'
Net Income Loss	-164,038	585,827	-359,402	-799,231	-1,420,437	-5,306,159	-4,521,196	-385,639	-315,030
Balance, in shares	'	'	'	'	'	'	'	'	'
Balance	($12,685,305)	($12,521,267)	($13,107,094)	($12,747,692)	($11,948,461)	($10,528,024)	($5,221,865)	($700,669)	($315,030)

DESCRIPTION_OF_BUSINESS_AND_BA

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	'
	NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
	CellCyte Genetics Corporation (the “Company”) is in the development stage, as defined by Financial Accounting Standards Board (“FASB”) ASC 915, “Development Stage Entities”, and its efforts are principally devoted to the commercialization of its cell expansion technology. To date, the Company has not generated any sales revenues, has incurred ongoing operating expenses and has sustained losses.  Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise.  For the period from inception through December 31, 2013, the Company has accumulated losses of $12,685,305.
	As shown in the accompanying financial statements, the Company has incurred significant losses since inception and has not generated any revenues to date. In addition, effective July 1, 2008, the Company suspended significantly all of its operations and placed all of its employees on unpaid leave. The future of the Company is dependent upon its ability to obtain sufficient financing and upon achieving future profitable operations. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.
	Basis of Consolidation
	These consolidated financial statements include the accounts of CellCyte Genetics Corporation, a private Washington corporation, since its incorporation on January 4, 2005 and its parent, CellCyte Genetics Corporation, a Nevada corporation, since the reverse acquisition on March 14, 2007. All inter-company balances and transactions have been eliminated.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments and short-term debt instruments with maturities of three months or less from date of purchase to be cash equivalents. The Company had no cash or cash equivalents at December 31, 2013.
	Income (Loss) per Share
	The Company computes net income (loss) per common share in accordance with FASB ASC 260, “Earnings Per Share”. Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. The Company uses the treasury stock method of calculating dilutive securities.
	The following table sets forth the calculation of basic and diluted earnings per share for the years ended December 31, 2013 and 2012. Basic and diluted earnings per share were the same for the year ended December 31, 2013 as including common stock equivalents in the calculation of diluted earnings per share would have been anti-dilutive.
				2013		2012
	Net income (loss)		$	-164,038	$	585,827
	Common shares outstanding – basic			82,329,481		82,329,481
	Earnings per share – basic		$	0	$	0.01
	Effect of dilutive securities
		Options		-		6,461,538
		Convertible notes		-		-
	Common shares outstanding – diluted			82,329,481		88,791,019
	Earnings per share – diluted		$	0	$	0.01
	Fair Value of Financial Instruments
	The Company's financial instruments may consist of cash and cash equivalents, prepaid expenses and other deferred charges, accounts payable, accrued expenses and other current liabilities. All instruments are accounted for on an historical cost basis, which, due to the short maturity of these financial instruments, approximates the fair value at the reporting dates of these financial statements.
	Intangible Assets
	The Company’s intangible assets primarily consist of patents and intellectual property, which are carried at the purchase price and/or the legal cost to obtain them less accumulated amortization. Patents and licenses are being amortized over their estimated useful lives, which range from seven to seventeen years.
	Going Concern
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred losses of $12,685,305 and used $5,394,365 in cash for operating activities from its inception through December 31, 2013. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company's existence is dependent upon management's ability to successfully raise additional capital and to develop profitable operations. Management is devoting substantially all of its efforts in raising capital and in developing its products and services and there can be no assurance that the Company's efforts will be successful. Management’s efforts could be further limited by the effects of certain ongoing investigations and litigation. The inability to raise new capital prior to the settling of uncertainties may substantially damage any current plans of continuing operations. The planned principal operations have not commenced and no assurance can be given that management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
	Income Taxes
	The Company follows the provisions of FASB ASC 740, “Income Taxes”, under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The provisions of ASC 740 also require the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that the realization of such benefits is more likely than not. To the extent that it is more likely than not that such benefits will not be received, the Company records a valuation allowance against the related deferred tax asset. Also, see Note 7 regarding additional income tax disclosures.
	Long-Lived Assets and Intangibles
	The Company examines on a periodic basis the carrying value of its tangible and intangible assets to determine whether there are any impairment losses. FASB ASC 360, “Property, Plant and Equipment”, establishes a single accounting model for long-lived assets to be disposed of by sale, including discontinued operations, and requires that these long-lived assets be measured at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or discontinued operations. The determination of any impairment would include a comparison of estimated future cash flows anticipated to be generated during the remaining life of the assets to the net carrying value of the assets.
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance are expensed as incurred.
	Research and Development Costs
	Research and development costs are expensed as incurred. The cost of intellectual property purchased from others that is immediately marketable or that has an alternative future use is capitalized and amortized as intangible assets. Capitalized costs are amortized using the straight-line method over the estimated economic life of the related asset. The Company periodically reviews its capitalized intangible assets to assess recoverability based on the projected undiscounted cash flows from operations, and impairments are recognized in operating results when a permanent diminution in value occurs.
	Recent Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. The Company expects to adopt ASU 2013-11 effective January 1, 2014 and does not expect this adoption to have a material impact on its financial condition, results of operations or cash flows.
	In February 2013, the FASB issued ASU No. 2013-02, which amends ASC Topic 220, Comprehensive Income and requires that entities present information about reclassification adjustments from accumulated other comprehensive income in their interim and annual financial statements. The standard requires that entities present either on the face of the income statement or as a separate note to the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income. If a component is not required to be reclassified to net income in its entirety, entities are required to cross reference to the related footnote for additional information. For public companies, the standard is effective for fiscal years and interim periods beginning after December 15, 2012. The Company adopted ASU 2013-02 on January 1, 2013 and this adoption did not have a material impact on the Company’s financial results or disclosures.
	Stock-Based Compensation
	The Company records stock-based compensation in accordance with FASB ASC 718, “Stock Compensation”. ASC 718 requires that the cost resulting from all share-based transactions be recorded in the financial statements. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The Statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
	The Company has recorded no stock-based compensation expense during the years ended December 31, 2013 and 2012.
	Use of Estimates
	The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America and include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results may differ from those estimates.

INTELLECTUAL_PROPERTY_AND_PROP

INTELLECTUAL PROPERTY AND PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
INTELLECTUAL PROPERTY AND PROPERTY AND EQUIPMENT	'
	NOTE 3 – INTELLECTUAL PROPERTY AND PROPERTY AND EQUIPMENT
	Intellectual Property
	In 2005, the Company acquired certain patents and intellectual property from Genespan Corporation relating to its cell expansion and maintenance technology for which it paid $70,002.
	The Company amortizes patents (and licenses for the use of patents) over the remaining life of the patents, which ranges from 7 to 17 years.
	During the years ended December 31, 2013 and 2012, the Company recognized amortization expense in the amounts of $16,218 and $7,504, respectively, included in general and administrative expense.
	Intellectual property was as follows as of December 31, 2013 and 2012:
		2013		2012
	Patents	$	70,002	$	70,002
	Accumulated amortization		-70,002		-53,784
	Patents, net	$	-	$	16,218
	Property and Equipment
	Property and equipment are stated at cost and are being depreciated using the straight-line basis over the assets’ estimated useful lives, which are generally three years for computer equipment, three to five years for office equipment, five to seven years for furniture, and five years for laboratory equipment. Tenant improvements are capitalized and amortized over the shorter of the lease term or their estimated useful life. Depreciation and amortization expense for the years ended December 31, 2013 and 2012 was $0 and $7,009, respectively. During the year ended December 31, 2012, the Company sold or disposed of equipment and supplies with no cost basis and no net book value for total proceeds of $1,985, resulting in a gain on disposal of $1,985.
	Property and equipment were as follows as of December 31, 2013 and 2012:
		2013		2012
	Laboratory equipment	$	40,935	$	40,935
	Computer and office equipment		79,810		79,810
	Accumulated depreciation and amortization		-120,745		-120,745
	Property and equipment, net	$	-	$	-

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 4 – COMMITMENTS AND CONTINGENCIES
	Operating Leases
	The Company currently rents office and lab space on a month-to-month basis.
	Settlements
	During the first quarter of 2012, the Company entered into negotiations with its previous landlord whereby it settled the entire amount of principal and interest outstanding on a promissory note for a final payment of $75,000. As a result of this settlement, the Company recorded a gain of $180,955 on the extinguishment of its debt to its landlord.

CAPITAL_STOCK

CAPITAL STOCK	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
CAPITAL STOCK	'
	NOTE 5 – CAPITAL STOCK
	Common Stock
	The Company has authorized 525,000,000 shares of its common stock, $0.001 par value. The Company had issued and outstanding 82,329,481 shares of its common stock at December 31, 2013 and December 31, 2012, respectively.
	During the year ended December 31, 2013, the Company issued no shares of common stock in exchange for services.
	Common Stock Warrants
	The Company’s common stock purchase warrant activity for the years ended December 31, 2013 and December 31, 2012 is as follows:
		Warrants		Weighted Average	Weighted Average
		Outstanding		Exercise Price	Remaining Life
	Balance, December 31, 2011	919,230	$	0.06	2.62 years
	Warrants issued	-		-
	Warrants exercised	-		-
	Warrants expired	-		-
	Balance, December 31, 2012	919,230		0.06	1.62 years
	Warrants issued	-		-
	Warrants exercised	-		-
	Warrants expired	-		-
	Balance, December 31, 2013	919,230	$	0.06	0.62 years
	Common Stock Options
	Effective March 30, 2007, the Company adopted the 2007 Stock Option/Restricted Stock Plan (the “2007 Plan”). The purpose of the 2007 Plan is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees and consultants and to promote the success the Company’s business. The number of shares approved for issuance under the 2007 Plan was 5,450,000 shares, of which 710,000 have been granted and are outstanding as of December 31, 2013. If an award under the 2007 Plan should expire or become unexercisable for any reason and without having been exercised in full or surrendered pursuant to an option exchange program, then the shares that were subject to such expiration or unexercised award shall again become available for future grant under the 2007 Plan. The 2007 Plan is administered by the Company’s Board of Directors or a committee appointed by the Board. The term of the 2007 Plan is ten years from the date of its adoption by the Board.
	On January 24, 2009, the Company approved and adopted the 2009 Stock Incentive Plan for Employees and Consultants (the “2009 Plan”). The purpose of the 2009 Plan is to provide employees and consultants of the Company with an increased incentive to make significant and extraordinary contributions to the long-term performance and growth of the Company, and to join the interests of employees and consultants with the interests of the stockholders of the Company. The number of shares available for issuance under the 2009 Plan is 86,000,000 shares (as revised on September 1, 2011), and have been registered with the Securities and Exchange Commission pursuant to a Form S-8 Registration Statement.
	Compensation for stock option awards is calculated using the Black-Scholes model, using the assumptions discussed in this note, and recognized over the vesting period.
	During the year ended December 31, 2013, the Company issued no shares under either of its stock option plans.
	The Company’s stock option activity under both the 2007 and 2009 Plans for the years ended December 31, 2013 and 2012 is as follows:
		Options		Weighted Average	Weighted Average
		Outstanding		Exercise Price	Remaining Life
	Balance, December 31, 2011	53,945,000	$	0.069	3.63 years
	Options granted	-		-
	Options exercised	-		-
	Options cancelled and expired	(775,000)		1.50
	Balance, December 31, 2012	53,170,000		0.049	2.68 years
	Options granted	-		-
	Options exercised	-		-
	Options cancelled and expired	(250,000)		0.4
	Balance, December 31, 2013	52,920,000	$	0.051	1.68 years

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 6 – RELATED PARTY TRANSACTIONS
	During the year ended December 31, 2008, two former officers, Gary Reys and Dr. Ronald Berninger, who were also members of the Company’s board of directors, advanced funds in the amount of $26,290 for their legal defense related to certain Company legal matters. During 2009, Dr. Berninger advanced an additional $6,465 for his defense. Under the Company’s Bylaws, the Company is required to provide for the legal defense of its officers and directors.
	On March 16, 2014, the outstanding balance to Dr. Berninger was converted into a convertible promissory note bearing interest at 8% with all interest and principal due on March 15, 2019.
	During the years ended December 31, 2013 and 2012, the Company incurred accounting expenses of $25,375 and $35,975, respectively, for services of a firm that is owned by one of the Company’s directors. The accounts payable balance owed to this related party at December 31, 2013 was $65,900.
	Convertible Promissory Notes
	On December 23, 2009, an officer of the Company loaned $25,000 to the Company in exchange for a convertible promissory note and a warrant to purchase 150,000 shares of common stock. The promissory note bears interest at the annual rate of eight percent and all interest and principal is due on December 22, 2014. The fair market value of the warrants of $3,000 was recorded as a discount on the promissory note. During 2013 this officer advanced the Company an additional $18,250 to help fund operating costs. On November 5, 2013, all outstanding amounts to this officer, including accrued interest of $8,177 and an advance of $6,142 included in accrued expenses, were rolled into a new promissory note bearing interest at 8% and convertible into common stock at any time, at the option of the holder, at the exchange rate of $0.01 per share. The outstanding balance on this convertible promissory note at December 31, 2013 was $56,969, net of unamortized discount of $600.
	During the year ended December 31, 2013, a stockholder of the Company advanced a total of $43,600 under a convertible promissory note to help pay for certain operating and debt service costs. On November 5, 2013, all outstanding amounts to this stockholder, including accrued interest of $50,243 were rolled into a new promissory note bearing interest at 8% and convertible into common stock at any time, at the option of the holder, at the exchange rate of $0.01 per share. The outstanding balance on this convertible promissory note at December 31, 2013 was $398,886.
	During the year ended December 31, 2013, the Company repaid a second stockholder of the Company a total of $1,887 under a convertible promissory note. On November 5, 2013, all outstanding amounts to this stockholder, including accrued interest of $4,812 and an advance in the amount of $1,137 included in accrued expenses were rolled into a new promissory note bearing interest at 8% and convertible into common stock at any time, at the option of the holder, at the exchange rate of $0.01 per share. The outstanding balance on this convertible promissory note at December 31, 2013 was $21,633.
	Stockholder Advances
	During the year ended December 31, 2007 a stockholder of the Company paid various outstanding payables on behalf of the Company. As of December 31, 2013 the Company owed this stockholder $107,949. These advances are unsecured, non-interest bearing with no set terms of repayment.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 7 – INCOME TAXES
	Income taxes are calculated in accordance with ASC Topic 740, "Income Taxes" ("ASC 740"), which requires the use of the liability method. Deferred tax assets and liabilities are recognized based on the difference between the financial statement carrying amounts of assets and liabilities and their respective tax bases. Inherent in the measurement of deferred balances are certain judgments and interpretations of enacted tax laws and published guidance with respect to applicability to the Company's operations.
	The Company adopted the provisions of ASC 740 related to uncertainty in income taxes in the first quarter of fiscal year 2007. These provisions prescribe a comprehensive model of how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return. Under these provisions, the Company recognizes a tax benefit when a tax position is more-likely-than-not to be sustained upon examination, based solely on its technical merits. The Company measures the recognized tax benefit as the largest amount of tax benefit that has greater than a 50% likelihood of being realized upon the ultimate settlement with a taxing authority. The Company reverses a previously recognized tax benefit if it determines that the tax position no longer meets the more-likely-than-not threshold of being sustained. The Company accrues interest and penalties related to unrecognized tax benefits in income tax expense.
	The Company's deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes, and (b) net operating loss carry forwards.
	At December 31, 2013 and 2012 the Company had gross deferred tax assets calculated at an expected rate of 34% of approximately $4,305,000 and $4,249,000, respectively, principally arising from net operating loss carry-forwards and stock compensation for income tax purposes. As management of the Company cannot determine that it is more likely than not that the Company will realize the benefit of the net deferred tax asset, a valuation allowance of $4,305,000 and $4,249,000 has been established at December 31, 2013 and 2012, respectively.
	For the year ended December 31, 2012, the Company utilized approximately $585,000 of its net operating loss carryforwards to offset net taxable income for the year. This resulted in a reduction of the Company’s gross deferred tax asset and related valuation allowance in the amount of $199,000.
	The significant components of the Company’s net deferred tax asset at December 31, 2013 and 2012 are as follows:
		2013	2012
	Gross deferred tax asset:
	Net operating loss carry forwards	$4,305,000	$4,249,000
	Gross deferred tax liabilities:
	Valuation allowance	-4,305,000	-4,249,000
	Net deferred tax asset	$ -	$ -
	At December 31, 2013 and 2012 the Company has net operating tax loss carry forwards of approximately $12,662,000 and $12,498,000, respectively, which will expire in the years 2025 through 2033. The primary difference between net operating losses for financial statement and income tax purposes are permanent differences related to the accounting for meals and entertainment.
	Although we believe that our estimates are reasonable, no assurance can be given that the final tax outcome of these matters will not be different than that which is reflected in our tax provisions. Ultimately, the actual tax benefits to be realized will be based upon future taxable earnings levels, which are very difficult to predict.
	The Company is currently delinquent on its tax filings. If the Company does file an income tax return in the future, management believes that no penalties will be assessed, since there will be no tax liability. The Internal Revenue Service (IRS) usually only assess penalties when taxes are owed. The Company may not be able to claim the entire net operating losses disclosed above due to not filing tax returns in prior years. Since the Company has not filed income tax returns, all tax years since the Company’s inception remain open to investigation by the IRS.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Note 8 – Fair Value of Financial Instruments
	The Company’s financial instruments as defined by ASC 825-10-50 include prepaid expenses, accounts payable, accrued expenses, and notes payable. All instruments are accounted for on a historical cost basis, which due to the short maturity of these financial instruments, approximates fair value at December 31, 2013. The standards under ASC 820 define fair value, establish a framework for measuring fair value in accordance with generally accepted accounting principles, and expand disclosures about fair value measurements. FASB ASC 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
	Level 1- Observable inputs such as quoted prices in active markets;
	Level 2- Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3- Unobservable inputs in which there is little of no market data, which require the reporting entity to develop its own assumptions.
	As allowed by current financial reporting standards, the Company has elected not to implement fair value recognition and reporting for all non-financial assets and non-financial liabilities except for those that are recognized or disclosed at fair value in the financial statements on a recurring basis, that is, at least annually.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Consolidation	'
	Basis of Consolidation
	These consolidated financial statements include the accounts of CellCyte Genetics Corporation, a private Washington corporation, since its incorporation on January 4, 2005 and its parent, CellCyte Genetics Corporation, a Nevada corporation, since the reverse acquisition on March 14, 2007. All inter-company balances and transactions have been eliminated.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments and short-term debt instruments with maturities of three months or less from date of purchase to be cash equivalents. The Company had no cash or cash equivalents at December 31, 2013.
Income (Loss) per Share	'
	Income (Loss) per Share
	The Company computes net income (loss) per common share in accordance with FASB ASC 260, “Earnings Per Share”. Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. The Company uses the treasury stock method of calculating dilutive securities.
	The following table sets forth the calculation of basic and diluted earnings per share for the years ended December 31, 2013 and 2012. Basic and diluted earnings per share were the same for the year ended December 31, 2013 as including common stock equivalents in the calculation of diluted earnings per share would have been anti-dilutive.
				2013		2012
	Net income (loss)		$	-164,038	$	585,827
	Common shares outstanding – basic			82,329,481		82,329,481
	Earnings per share – basic		$	0	$	0.01
	Effect of dilutive securities
		Options		-		6,461,538
		Convertible notes		-		-
	Common shares outstanding – diluted			82,329,481		88,791,019
	Earnings per share – diluted		$	0	$	0.01
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company's financial instruments may consist of cash and cash equivalents, prepaid expenses and other deferred charges, accounts payable, accrued expenses and other current liabilities. All instruments are accounted for on an historical cost basis, which, due to the short maturity of these financial instruments, approximates the fair value at the reporting dates of these financial statements.
Intangible Assets	'
	Intangible Assets
	The Company’s intangible assets primarily consist of patents and intellectual property, which are carried at the purchase price and/or the legal cost to obtain them less accumulated amortization. Patents and licenses are being amortized over their estimated useful lives, which range from seven to seventeen years.
Going Concern	'
	Going Concern
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred losses of $12,685,305 and used $5,394,365 in cash for operating activities from its inception through December 31, 2013. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
	The Company's existence is dependent upon management's ability to successfully raise additional capital and to develop profitable operations. Management is devoting substantially all of its efforts in raising capital and in developing its products and services and there can be no assurance that the Company's efforts will be successful. Management’s efforts could be further limited by the effects of certain ongoing investigations and litigation. The inability to raise new capital prior to the settling of uncertainties may substantially damage any current plans of continuing operations. The planned principal operations have not commenced and no assurance can be given that management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
Income Taxes	'
	Income Taxes
	The Company follows the provisions of FASB ASC 740, “Income Taxes”, under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The provisions of ASC 740 also require the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that the realization of such benefits is more likely than not. To the extent that it is more likely than not that such benefits will not be received, the Company records a valuation allowance against the related deferred tax asset. Also, see Note 7 regarding additional income tax disclosures.
Long-Lived Assets and Intangibles	'
	Long-Lived Assets and Intangibles
	The Company examines on a periodic basis the carrying value of its tangible and intangible assets to determine whether there are any impairment losses. FASB ASC 360, “Property, Plant and Equipment”, establishes a single accounting model for long-lived assets to be disposed of by sale, including discontinued operations, and requires that these long-lived assets be measured at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or discontinued operations. The determination of any impairment would include a comparison of estimated future cash flows anticipated to be generated during the remaining life of the assets to the net carrying value of the assets.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance are expensed as incurred.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are expensed as incurred. The cost of intellectual property purchased from others that is immediately marketable or that has an alternative future use is capitalized and amortized as intangible assets. Capitalized costs are amortized using the straight-line method over the estimated economic life of the related asset. The Company periodically reviews its capitalized intangible assets to assess recoverability based on the projected undiscounted cash flows from operations, and impairments are recognized in operating results when a permanent diminution in value occurs.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standards Update (“ASU”) No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. The Company expects to adopt ASU 2013-11 effective January 1, 2014 and does not expect this adoption to have a material impact on its financial condition, results of operations or cash flows.
	In February 2013, the FASB issued ASU No. 2013-02, which amends ASC Topic 220, Comprehensive Income and requires that entities present information about reclassification adjustments from accumulated other comprehensive income in their interim and annual financial statements. The standard requires that entities present either on the face of the income statement or as a separate note to the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income. If a component is not required to be reclassified to net income in its entirety, entities are required to cross reference to the related footnote for additional information. For public companies, the standard is effective for fiscal years and interim periods beginning after December 15, 2012. The Company adopted ASU 2013-02 on January 1, 2013 and this adoption did not have a material impact on the Company’s financial results or disclosures.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company records stock-based compensation in accordance with FASB ASC 718, “Stock Compensation”. ASC 718 requires that the cost resulting from all share-based transactions be recorded in the financial statements. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The Statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
	The Company has recorded no stock-based compensation expense during the years ended December 31, 2013 and 2012.
Use of Estimates	'
	Use of Estimates
	The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America and include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results may differ from those estimates.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share	'
				2013		2012
	Net income (loss)		$	-164,038	$	585,827
	Common shares outstanding – basic			82,329,481		82,329,481
	Earnings per share – basic		$	0	$	0.01
	Effect of dilutive securities
		Options		-		6,461,538
		Convertible notes		-		-
	Common shares outstanding – diluted			82,329,481		88,791,019
	Earnings per share – diluted		$	0	$	0.01

INTELLECTUAL_PROPERTY_AND_PROP1

INTELLECTUAL PROPERTY AND PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Intellectual Property	'
		2013		2012
	Patents	$	70,002	$	70,002
	Accumulated amortization		-70,002		-53,784
	Patents, net	$	-	$	16,218
Schedule of Property Plant and Equipment	'
		2013		2012
	Laboratory equipment	$	40,935	$	40,935
	Computer and office equipment		79,810		79,810
	Accumulated depreciation and amortization		-120,745		-120,745
	Property and equipment, net	$	-	$	-

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Common Stock Warrants	'
		Warrants		Weighted Average	Weighted Average
		Outstanding		Exercise Price	Remaining Life
	Balance, December 31, 2011	919,230	$	0.06	2.62 years
	Warrants issued	-		-
	Warrants exercised	-		-
	Warrants expired	-		-
	Balance, December 31, 2012	919,230		0.06	1.62 years
	Warrants issued	-		-
	Warrants exercised	-		-
	Warrants expired	-		-
	Balance, December 31, 2013	919,230	$	0.06	0.62 years
Common Stock Options	'
		Options		Weighted Average	Weighted Average
		Outstanding		Exercise Price	Remaining Life
	Balance, December 31, 2011	53,945,000	$	0.069	3.63 years
	Options granted	-		-
	Options exercised	-		-
	Options cancelled and expired	(775,000)		1.50
	Balance, December 31, 2012	53,170,000		0.049	2.68 years
	Options granted	-		-
	Options exercised	-		-
	Options cancelled and expired	(250,000)		0.4
	Balance, December 31, 2013	52,920,000	$	0.051	1.68 years

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Taxes	'
		2013	2012
	Gross deferred tax asset:
	Net operating loss carry forwards	$4,305,000	$4,249,000
	Gross deferred tax liabilities:
	Valuation allowance	-4,305,000	-4,249,000
	Net deferred tax asset	$ -	$ -

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended		108 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Gain on Extinquisment of debt	'	($180,955)	($53,547)